Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
228.3(c) 228.5(c) 227.8(c) 229(c) 230.1 Last
996 917 1 325 378 1 202 611 1 436 424 2 371 498 Volume
+0.26% +0.09% -0.31% +0.53% +0.48% Change
More quotes
Financials ( CHF)
Sales 2017 53 394 M
EBIT 2017 18 161 M
Net income 2017 11 138 M
Debt 2017 10 106 M
Yield 2017 3,76%
Sales 2018 55 447 M
EBIT 2018 19 132 M
Net income 2018 12 335 M
Debt 2018 5 745 M
Yield 2018 3,94%
P/E ratio 2017 17,06
P/E ratio 2018 15,68
EV / Sales2017 3,92x
EV / Sales2018 3,69x
Capitalization 199 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
11/16Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
10:40a ROCHE : FDA approves Roche's Hemlibra (emicizumab-kxwh) for haemophilia A with i..
07:42aDJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
07:31aDJROCHE : to Acquire U.S. Software Company Viewics
07:08a ROCHE : to acquire Viewics, Inc. to provide data-driven lab business analytics a..
07:08a ROCHE : FDA approves Roche’s Gazyva for previously untreated advanced foll..
06:57a ROCHE : Pioneers Study on Hurdles of Breast Cancer Care in Nigeria, Other Countr..
11/16 CHUGAI PHARMACEUTICAL : ALK Inhibitor "Alecensa®" Approved for the Treatment of ..
11/16 ROCHE : FDA OKs new therapy for some hemophilia patients
11/16 ROCHE : Diagnostic Reagents
11/16 ROCHE : FDA Approves Genentech’s Gazyva for Previously Untreated Advanced ..
More news
Sector news : Pharmaceuticals - NEC
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/16 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
11/15 BAYER : Monsanto, U.S. farm groups sue California over glyphosate warnings
11/15DJMERCK AND : Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases -- Upda..
11/15DJBILL GATES : Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
ROCHE HOLDING LTD. - 2016
An opportunity over the medium term?
BUY
ROCHE HOLDING LTD. - 2016
A medium term support level to take advantage of
BUY
More Strategies
News from SeekingAlpha
09:31a YOUR DAILY PHARMA SCOOP : Gilead CAR-T Potential, Egalet Surges, Aerie Launches ..
08:00a 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 17, 2017
07:42a AstraZeneca to present new late-stage data on cancer drugs at ESMO Asia
06:59a Roche buys lab analytics firm Viewics
06:54a FDA OKs new use for Roche's blood cancer med Gazyva
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 271  CHF
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-2.06%200 423
JOHNSON & JOHNSON20.74%373 077
NOVARTIS10.73%218 225
PFIZER8.87%211 963
MERCK AND COMPANY-6.91%150 468
AMGEN15.85%123 964